EP2453747A1 — Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts

USPTO Abstract

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1 isobuty 1-1 H-imidazo [4, 5 -c] -quinolin-4-amine or 1 -(2-methylpropyl)- 1 H-imidazo [4,5 -c] quinolin-4-arnme, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara ® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara ® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.